1 Germline *RUNX1* Variation and Predisposition to Childhood Acute Lymphoblastic

2 Leukemia

Yizhen Li, PhD^{1,}, Meenakshi Devidas, PhD², Wentao Yang, PhD¹, Stuart S. Winter, MD³, Wenjian
Yang, PhD¹, Kimberly P. Dunsmore, MD⁴, Colton Smith, PhD¹, Maoxiang Qian, PhD⁵, Xujie Zhao,
MS¹, Ranran Zhang, MS¹, Julie M. Gastier-Foster, PhD⁶, Elizabeth A. Raetz, MD⁷, William L.
Carroll, MD⁷, Chunliang Li, PhD⁸, Paul P. Liu⁹, Karen R. Rabin, MD, PhD¹⁰, Takaomi Sanda^{11,12},
Charles G. Mullighan, MBBS, MD¹³, Kim E. Nichols, MD¹⁴, William E. Evans, PharmD^{1,15}, ChingHon Pui, MD^{14,15}, Stephen P. Hunger, MD¹⁶, David T. Teachey¹⁷, MD, Mary V. Relling, PharmD^{1,14},
Mignon L. Loh, MD¹⁸, Jun J. Yang, PhD^{1, 14, 15 f}

10 ¹Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, 11 ²Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN, 12 3 Children's Minnesota Research Institute, Children's Minnesota, Minneapolis, MN, 4 Children's 13 Hematology and Oncology, Carilion Clinic and Virginia Tech Carilion School of Medicine, 14 Roanoke, VA, ⁵Children's Hospital and Institutes of Biomedical Sciences, Fudan University, 15 Shanghai, China, ⁶Baylor College of Medicine and Texas Children's Hospital, Houston, TX, 16 ⁷Division of Pediatric Hematology and Oncology, Perlmutter Cancer Center, New York University 17 Langone Health, New York, ⁸Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, TN. ⁹Oncogenesis and Development Section, National Human Genome Research Institute, 18 19 National Institutes of Health, Bethesda, MD, USA, ¹⁰Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, TX, ¹¹Cancer Science Institute of Singapore, 20 National University of Singapore, Singapore, ¹²Department of Medicine, Yong Loo Lin School of 21 Medicine, National University of Singapore, Singapore, ¹³Department of Pathology. St. Jude 22 23 Children's Research Hospital, Memphis, TN, ¹⁴Department of Oncology, St. Jude Children's 24 Research Hospital, Memphis, TN, ¹⁵Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN, ¹⁶Department of Pediatrics and Center for Childhood Cancer 25 26 Research, Children's Hospital of Philadelphia and the Perelman School of Medicine at the 27 University of Pennsylvania, Philadelphia, PA, ¹⁷Division of Oncology, Department of Pediatrics, 28 Center for Childhood Cancer Research, Children's Hospital of Philadelphia and Perelman School 29 of Medicine, University of Pennsylvania, Philadelphia, PA, ¹⁸Department of Pediatrics, Benioff 30 Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of 31 California San Francisco, San Francisco, CA

33 Abstract

34 RUNX1 is a transcription factor critical for definitive hematopoiesis and genetic alterations in 35 RUNX1 have been implicated in both benign and malignant blood disorders, particularly of the 36 megakaryocyte and myeloid lineages. Somatic RUNX1 mutations are reported in B- and T-cell 37 acute lymphoblastic leukemia (B-ALL and T-ALL), but germline genetic variation of RUNX1 in 38 these lymphoid malignancies have not been comprehensively investigated. Sequencing 4.836 39 children with B-ALL and 1,354 cases of T-ALL, we identified 31 and 18 unique germline RUNX1 40 variants in these two ALL subtypes, respectively. RUNX1 variants in B-ALL were predicted to 41 have minimal impact. By contrast, 54.5% of variants in T-ALL result in complete or partial loss of 42 RUNX1 activity as a transcription activator in vitro, with dominant negative effects for 4 variants. 43 Ectopic expression of dominant negative deleterious RUNX1 variants in human CD34+ cells 44 repressed differentiation into erythroid, megakaryocytes, and T cells, while promoting 45 differentiation towards myeloid cells. We then performed chromatin immunoprecipitation profiling 46 in isogenic T-ALL models with variants introduced by genome editing of endogenous RUNX1. We 47 observed highly distinctive patterns of DNA binding and target genomic loci by RUNX1 proteins 48 encoded by the truncating vs missense variants. The p.G365R RUNX1 variant resulted in a novel 49 methylation site in RUNX1 and alteration in its interaction with CBFβ. Further whole genome 50 sequencing showed that JAK3 mutation was the most frequent somatic genomic abnormality in 51 T-ALL with germline RUNX1 variants. Consistently, co-introduction of RUNX1 variant and JAK3 52 mutation in hematopoietic stem and progenitor cells in mouse gave rise to T-ALL with early T-cell 53 precursor phenotype in vivo, compared to thymic T-ALL seen in mice with JAK3 mutation alone. 54 Taken together, these results indicated that RUNX1 is an important predisposition gene for ALL, 55 especially in T-ALL and also pointed to novel biology of RUNX1-mediated leukemogenesis in the 56 lymphoid lineages.

58 Introduction

59 Acute lymphoid leukemia (ALL) is the most common cancer in children. The exact cause of ALL 60 is incompletely understood, although somatic genomic abnormalities are well documented 61 affecting a wide range of signaling pathways. There is also growing evidence of inherited 62 susceptibility to ALL. For example, common genetic polymorphisms in genes such as IKZF1(1), 63 ARID5B (2), CDKN2A(3), GATA3 (4, 5), CEBPE(6), and PIP4K2A(7) are associated with the risk 64 of ALL in an age- and subtype-dependent manner. On the other hand, rare germline variants have 65 been linked to familial predisposition to childhood ALL, and collectively about 5% of sporadic ALL 66 cases harbor pathogenic variants in TP53(8), ETV6(9), and IKZF1(1). These findings point to a 67 strong genetic basis of inter-individual variability in ALL risk. 68 The RUNX1 protein plays key roles in definitive hematopoiesis (10). RUNX1 functions as a 69 transcription factor by forming a heterodimer with core binding factor β (CBF β). RUNX1 consists 70 of a Runt homology domain (RHD) responsible for DNA binding and cofactor interaction (11) and 71 the C-terminal transcriptional activation domain (TAD) that recruits co-activators and activates the 72 expression of RUNX1 target genes (12). RUNX1 germline variants are associated with familial 73 platelet disorder (FPD). Many patients with FPD develop leukemia later in life, predominately 74 acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (13-16). Somatic RUNX1 75 mutations, most of which occur in the RHD and TAD, have been identified in both B- and T-76 ALL(17). RUNX1 mutation is related to poor prognosis in T-ALL(17). Although somatic and 77 germline RUNX1 variants associated with ALL have been reported, their pattern, prevalence, and 78 functional consequences in B-ALL and T-ALL have not been comprehensively investigated. 79 Here we report results from targeted germline sequencing of 6,190 children with B- or T-ALL

80 enrolled in frontline Children's Oncology Group (COG) and St. Jude Children's Research

81 Hospital (St. Jude) ALL trials. We observed a lineage-specific pattern of germline variation in the

- 82 RUNX1 gene, with deleterious variants exclusively present in T-ALL patients. Furthermore, we
- 83 experimentally characterized RUNX1 variants for their effects on transcription factor activity,

- 84 subcellular localization, cofactor interaction, *in vitro* hematopoiesis, and genome wide RUNX1
- 85 binding profile. Finally, we examined the somatic genomic landscape of T-ALL arising from
- 86 *RUNX1* germline variants and modeled *RUNX1*-mediated leukemogenesis in mouse models.

87 Results

88 Identification of germline *RUNX1* variants in pediatric ALL

89 To comprehensively characterize inherited RUNX1 variations in ALL, we performed targeted 90 sequencing in germline DNA of 4,836 patients with newly diagnosed B-ALL and 1,354 patients with T-ALL enrolled on COG and SJCRH frontline trials (Figure 1A and Table 1). We identified 91 92 31 unique variants in 61 B-ALL cases and 18 unique variants in 26 T-ALL cases. Seven of these 93 variants were found in both B- and T-ALL (Figure 1A and Table 1). 94 Of the 31 variants in B-ALL, 6 were not observed in the general population (Genome 95 Aggregation database, gnomAD, n = 15,496), 18 were rare with a maximum allele frequency of 96 0.00122%, and the remaining 7 were considered common variants with allele frequency > 97 0.01% (Figure 1A and Table 1). All the variants in B-ALL except one were missense, most of 98 which are in the C-terminus distal to the DNA binding runt-homology domain (RHD, Figure 1B). 99 Of the 18 variants in T-ALL cases, 8 were absent in the gnomAD dataset, 5 were rare with a 100 maximum allele frequency of 0.00239%, and the remaining 5 were common variants (Figure 1A 101 and Table 1). 27.8% of variants identified in T-ALL were frameshift or nonsense, including 102 p.K117* and p.S141fs which truncated both the RHD and the transcription activation domain 103 (TAD, Figures 1B and S1) and p.Q213fs, p.R232fs, and p.Y287* that resulted in the loss of 104 TAD only (Figure S1). Seven missense and 1 in-frame deletion variants in T-ALL were 105 distributed across RUNX1. This pattern of variant distribution is significantly different from 106 RUNX1 germline variants in familial platelet disorder with associated myeloid malignancy 107 (Figure 1C)(18), in which the majority of missense variants are localized in the DNA-binding 108 domain (RHD).

Effects of *RUNX1* variants on transcriptional regulation, cellular localization, and protein– protein interaction

111 To understand how germline *RUNX1* variants affect gene function, we first examined their 112 transcription activator activity using the luciferase reporter assay in Hela cells. With *SPI1* as the

113 RUNX1 target gene (19), none of the germline variants identified in B-ALL showed a significant 114 impact on reporter gene transcription compared to the wildtype protein and therefore were not 115 studied further (Figure 2A). Among RUNX1 alleles seen in T-ALL, all frameshift and nonsense 116 variants (p.K117*, p.S141fs, p.S213fs, p.R232fs, and p.Y287*) and also missense variant G365R 117 caused significant reduction of RUNX1 activity in this assay (Figure 2B). To further characterize 118 these RUNX1 variants in a more relevant cellular context, we engineered the Jurkat T-ALL cell 119 line in which each RUNX1 variant of interest was individually inserted into the safe harbor AAVS1 120 locus (Figure S2)(20) and a GFP tag was added to the C-terminus of RUNX1 target gene 121 GZMA(21) (Figure 2C and S3). Using this model system, RUNX1 transactivation activity could 122 be directly measured as the GFP intensity in RUNX1 variants knock-in cells, in the presence of 123 endogenous RUNX1 (Figure 2D). As shown in Figure 2E, the introduction of WT RUNX1 as well 124 as most missense variants (p.N153Y, p.T246M, p.A329T, p.P359R, and p.M418V) led to robust 125 GFP signals relative to cells with no RUNX1 insertion at the AAVS locus, confirming wildtype like 126 transcription activator activity. By contrast, cells with K117* and S141fs showed only baseline 127 GFP signals, indicating complete loss of RUNX1 function. Insertion of the p.Q213fs, p.R232fs, 128 p.Y287*, and p.G365R variants resulted in the lowest GFP intensity, suggesting these variants 129 not only lost their transcription activator activity but also repressed endogenous RUNX1 in a 130 plausibly dominant-negative manner.

131 We next analyzed subcellular localization and CBF_β cofactor interaction of all deleterious variants, 132 including p.K117*, p.S141fs, p.Q213fs, p.R232fs, p.Y287*, and p.G365R (Figure S1). 133 Fluorescence microscopy of HEK293T cells ectopically expressing RUNX1 variants showed that 134 p.K117* and p.S141fs proteins were mis-localized to the cytoplasm, whereas p.Q213fs, p.R232fs, 135 p.Y287*, p.G365R proteins remained in the nucleus (Figure 2F). In co-immunoprecipitation assay, 136 p.K117* and p.S141fs variant proteins were no longer associated with CBFβ most likely due to 137 the absence of RHD, whereas all the other variants retained the ability to interact with this co-138 factor (Figure 2G).

139 Effects of *RUNX1* variants on the differentiation and proliferation of human cord blood

140 CD34+ cells in vitro

We next sought to examine the effects of *RUNX1* variants on hematopoietic differentiation *in vitro* using human cord blood CD34+ cell as the model system. Because p.K117* and p.S141fs simply resulted in complete loss of function with no dominant negative effects, we chose not to further characterize them. For the remaining deleterious variants, we selected p.R232fs, p.Y287* and p.G365R to represent frameshift, nonsense, and missense variants, respectively (**Figure S4**). RUNX1 variants were ectopically expressed in human CD34+ cells which were then subjected to differentiation, proliferation, and apoptosis assays *in vitro* (**Figure 3A**).

In colony formation assays conditioned for erythroid and myeloid progenitor cell growth, the expression of p.R232fs, p.Y287*, and p.G365R significantly repressed burst-forming unit erythroid (BFU-E) and increased colony-forming unit granulocyte-macrophage (CFU-GM) colonies compared to CD34+ cells transduced with WT RUNX1 (**Figure 3B**). The immunophenotype of these progenitor cells were also confirmed by flow cytometry (**Figure S5A**). Long-term culture showed that the *RUNX1* variant-transduced CD34+ cells proliferated faster with concomitant reduction in apoptosis, compared to WT *RUNX1* transduced cells (**Figure 3C-D and S5B**).

With culture conditions for megakaryocyte differentiation, expression of RUNX1 variants consistently resulted in a significant reduction of CD41a+/CD42b+ population compared to WT (**Figure 3E**). These RUNX1 variants also significantly repressed the generation of CD5+/CD7+ T cells from the CD34+ population (**Figure 3F**). Collectively, these results suggested that *RUNX1* variants promoted myeloid differentiation while repressing megakaryocyte and T-cell differentiation *in vitro*.

RUNX1 variants have highly distinctive patterns of DNA binding and are associated with altered post-translational modifications

163 To understand the molecular effects of *RUNX1* variants, we comprehensively profiled RUNX1 164 binding across the genome using chromatin immunoprecipitation-sequencing (ChIP-seq). We first

165 engineered three isogenic Jurkat cell lines in which each of the three *RUNX1* variants (p.R232fs, p.Y287*, and p.G365R) was individually knocked-in at the endogenous locus in a hemizygous 166 167 fashion to represent heterozygous genotype seen in patients (Figure 4A and 4B). In these 168 models, we introduced the HA tag and TY1 epitope tags at the 3' end of the coding exon on the 169 variant and WT RUNX1 alleles, respectively (Figure S6-S10). This enabled us to separately 170 profile variant or WT RUNX1 binding using HA or TY1 antibodies (Figure S9C-D and S10C-D). 171 We also generate two single clones, in which both allele were wildtype RUNX1, but tagged with 172 HA and TY1 seperately (Figure S8 and S10).

173 ChIP-seq showed that all three variants have a largely overlapping binding profile as WT RUNX1 174 in T-ALL genome (**Figure 4C**). However, the C-terminal truncating variants p.R232fs and p.Y287* 175 exhibited a much similar binding pattern compared with missense p.G365R variant and wildtype 176 RUNX1 (**Figure 4D and S11**), as evidenced by the pearson correlation coefficient of ChIP-seq 177 signals. Even though these variant proteins maintained the DNA binding domain, their DNA 178 binding preference was different from wildtype or full-length missense mutation RUNX1.

Interestingly, the p.G365R variant gave rise to a novel methylation site in RUNX1, with mono- or di-methylation of the arginine residue confirmed by mass spectrometry and Western blot analysis (Figure 4E and 4F). Immunoprecipitation–mass spectrometry results suggested that RUNX1 protein methylation at this site may disrupt its interaction with TUBB family proteins (TUBB2A, TUBB2B, TUBB4B, TUBB5, TUB8, *et al.*) and heat shock proteins, but with an increase of CBFβ binding (Table S1).

185 Somatic genomic abnormalities in T-ALL with germline *RUNX1* variants

To characterize the somatic genomic landscape of T-ALL with germline *RUNX1* variants, we analyzed whole genome seq of six cases with p.K117*, p.S141fs, p.Q213fs, p.R232fs, p.Y287*, and p.G365R variants, which were contrasted with 263 T-ALL with somatic mutations in *RUNX1* or WT genotype (22). Five of six T-ALL (83.3%) with germline *RUNX1* variants had a somatic *JAK3* mutation, significantly higher compared to the frequency of *JAK3* mutation percentage in T- ALL cases without germline variants in *RUNX1* (7.6%, p-value = 2.59×10^{-5}) (22) or T-ALL cases with somatic mutations in *RUNX1* (27.3%, p-value = 0.05) (**Figure 5A**). *JAK3* mutations in T-ALL cases with germline *RUNX1* variants were located in either the pseudo-kinase domain (M5111 and R657Q) or in the kinase domain (L950V, **Figure S12 and Tables S2 and S3**). Of interest, the patient with a germline *RUNX1*-R232fs variant also subsequently acquired a somatic *RUNX1* mutation (R169_E5splice_region).

We also performed RNA-seq of T-ALL with germline *RUNX1* variants and compared the expression profile with cases with germline *RUNX1* variants, somatic *RUNX1* mutations or WT *RUNX1* (N = 4, 11 and 252, respectively). Based on hierarchical clustering of global expression profile, *RUNX1*-variant cases (either germline or somatic) consistently clustered with T-ALL with early T-cell precursor immunophenotype (ETP) or near-ETP cases (**Figure 5B**). These results are consistent with previous reports of the preponderance of *RUNX1* variants in ETP T-ALL (23). *RUNX1* and *JAK3* mutation-induced ETP phenotype in murine bone marrow

204 transplantation model

205 To model RUNX1-related T-ALL leukemogenesis, especially in conjunction with somatic JAK3 206 mutation, we introduced different combinations of RUNX1 and JAK3 mutations (RUNX1^{R232fs} and 207 JAK3^{M511/}) into mouse hematopoietic progenitor cells (Lin⁻/Sca-1⁺/C-Kit⁺) and monitored leukemia 208 development in vivo after transplantation. We hereafter refer to recipient mice with LSK cells transduced with empty vector, RUNX1^{R232fs}, JAK3^{M5111}, and JAK3^{M5111}/RUNX1^{R232fs} as "control", 209 210 "RUNX1^M", "JAK3^M", and "JAK3^MRUNX1^M" mice, respectively. At 4 months, peripheral leukocyte 211 counts of JAK3^M and JAK3^M RUNX1^M mice (41.78 ± 44.3 E3 cells/ μ L and 14.93 ± 3.42 E3 cells/ μ L 212 respectively) were significantly higher than control mice (8.84 \pm 2.00 cells/µL), and the lowest 213 peripheral leukocyte counts were seen in $RUNX1^{M}$ mice (6.10 ± 2.03 cells/µL, Figure S13A). Flow 214 cytometry analysis at this time point showed a significant increase of CD8+ T cells in JAK3^M mice 215 (Figure S13B and C), compared with control mice. By contrast, JAK3^M RUNX1^M mice showed an

increase in Mac1+ population and lower T cell population, suggesting an outgrowth of cells with
 ETP immunophenotype (Figure S13B and C).

218 At 6 to 10 months after transplantation, both *JAK3^MRUNX1^M* and *JAK3^M* mice developed overt 219 leukemia presented with leukocytosis and splenomegaly, with 66.7% and 100% mice developed leukemia, respectively (Figure 5C-E and S14). The thymus of JAK3^MRUNX1^M mice showed a 220 221 significantly increase of CD4-CD8- (DN) T cells, particularly DN1 cells, as compared with JAK3^M 222 mice (Figure 5F-G). Circulating leukemic cells of JAK3^M RUNX1^M mice showed a markedly higher 223 Mac1+ population, but lower lymphoid surface marker as compared with JAK3^M mice (Figure 5H). 224 Also, flow analysis of spleen and bone marrow showed a similar leukemia immunophenotype as 225 peripheral blood (Figure 5H). These results indicate that JAK3^MRUNX1^M induced the ETP-ALL 226 phenotype in vivo. There was also a trend for higher Mac1+ cells with lower level of CD3+ cells 227 in the peripheral blood of RUNX1^M mice but they never developed leukemia within this timeframe 228 (Figure S13).

230 **Discussion**

231 RUNX1 plays significant roles in definitive hematopoiesis by regulating the differentiation of 232 myeloid, megakaryocyte, and lymphoid lineages. In this study, we comprehensively investigated 233 RUNX1 variants in germline ALL samples from patients and identified highly deleterious germline 234 RUNX1 variants in T-ALL cases, most of which were frameshift or nonsense variations. By 235 multilayer functional experiments and comprehensive epigenomic and genomic profiling analyses, 236 we systematically characterized RUNX1 variant functions and identified JAK3 mutations as 237 predominant co-operating somatic lesions in T-ALL. Furthermore, RUNX1 variant, in conjunction 238 with mutant JAK3, directly gave rise to ETP-ALL in vivo. These findings advance our 239 understanding of the role of *RUNX1* in the predisposition to childhood ALL.

240 As a crucial transcription factor that regulates the hematopoietic differentiation of multiple lineages, 241 RUNX1 is one of the most frequent target genes of chromosomal translocation, mutation, and 242 copy number alteration in different hematopoietic diseases and leukemia. RUNX1 germline 243 variants are associated with familial platelet disorder with associated myeloid malignancy 244 (FPDMM, OMIM #601399), also known as FPD or FPD/AML (13, 14, 16, 24). Although most 245 patients with FPD progress to myeloid malignancies, ALL has been reported in a minority of cases 246 (14, 15). In MDS and AML with germline RUNX1 variants, somatic RUNX1 mutations are the most 247 frequently observed genomic alteration, suggesting they are one of the cooperating events for 248 leukemia progression (18, 25). Other studies identified somatic mutations in CDC25C, GATA2, 249 BCOR, PHF6, JAK2, DNMT3A, TET, ASXL1 albeit with lower frequencies (18, 25, 26). By contrast, 250 we identified JAK3 mutations as the predominant co-occurring event with RUNX1 germline 251 variants in T-ALL, which consistently drove an ETP phenotype in patients and in mouse models. 252 Therefore, we postulate that while germline RUNX1 variants disrupt normal hematopoiesis and 253 generally increase the risk of leukemia, the lineage specification of these hematological 254 malignancies is mostly dictated by secondary mutations acquired later in life.

255 Activating JAK3 mutations have been reported in T-ALL (23). In vivo studies using a murine bone marrow transplantation model showed that JAK3 mutations in the pseudo-kinase domain caused 256 257 T-cell lymphoproliferative disease that progressed to T-ALL, mainly by increasing the CD8+ cell 258 population (27, 28). This is in line with our observation that *JAK3^M* mice exhibited a significant accumulation of CD8+ cells in thymus, peripheral blood, spleen, and bone marrow. However, 259 260 JAK3^MRUNX1^M mouse developed lymphoid leukemia with a completely distinctive phenotype 261 which recapitulated human ETP T- ALL features similar to previous reported ETP-ALL mouse 262 models (e.g., circulating leukemic cells expressed the myeloid cell marker Mac1, but not the 263 lymphoid markers CD8/CD3)(29, 30). Also, the CD4-CD8- (DN), especially DN1 population was particularly enriched in thymocytes from JAK3^MRUNX1^M mice, as compared with JAK3^M mice. 264 265 Alongside genomic findings in T-ALL patients, these in vivo experiments indicate that RUNX1 266 dominant-negative variants plus JAK3-activating mutations most likely result in the ETP T-ALL. 267 A recent study by Brown et al. comprehensively described the genomic landscape of RUNX1-268 related FPD and myeloid malignancy from 130 families (18). In this cohort, missense and 269 truncating germline RUNX1 variants were equally represented. While truncating variants occurred 270 in both the RUNT domain and the activation domain, missense variants were largely restricted to 271 the DNA-binding RUNT domain. This pattern is significantly different from that in the lymphoid 272 malignancies as described herein. In T-ALL, deleterious RUNX1 variants were predominantly 273 nonsense or frameshift and the only missense variant resided in the activation domain. 274 Unfortunately, we do not have family history for children with T-ALL carrying RUNX1 germline 275 variants, and therefore cannot ascertain the exact penetrance on leukemia or FPD. However, 276 given the profound effects on RUNX1 activity and a range of phenotypes in vitro and in vivo, these 277 variants are likely to be pathogenic. In fact, the Y287* variant seen in our T-ALL cohort has been 278 previously linked to FPD and functional characterization indicated that this variant causes 279 defective megakaryocyte differentiation in the iPSC model (31). In B-ALL, almost all variants were 280 missense and localized outside of RUNT domain, likely with little effects on RUNX1 activity.

Although these variants showed little effects on RUNX1 transcriptional activity level, some of them were predicted to be damaging variants by polyphen2 and SIFT (Table 1). More comprehensive functional assays might be needed to definitively determine the effects of these variants.

284 Genome-wide patterns of RUNX1 binding have been investigated extensively using ChIP-seq 285 assays (21, 32, 33), but there is a paucity of studies directly examining target genes of variant 286 RUNX1. When this was attempted in the past, variant RUNX1 was either ectopically expressed 287 in iPSC or cord blood CD34+ cells, raising the possibility of false positives due to artificially high 288 levels of RUNX1(34). This is also hindered by the lack of antibodies that specifically recognize 289 wildtype but not variant RUNX1. To overcome these issues, we engineered Jurkat cells with 290 heterozygous knock-in of RUNX1 variants (p.R232fs/WT, p.Y287*/WT, and p.G365R/WT) using 291 the CHASE-KI method (35). In this model, we also introduced the HA and TY1 epitope tags at the 292 3' end of the coding exon on the variant and WT RUNX1 allele, respectively. Our model 293 recapitulated RUNX1 variant status in patients with T-ALL and enabled us to profile variant or 294 wildtype RUNX1 binding using different antibodies. Moreover, our ChIP-seg result indicated that 295 the C-terminal truncating variants p.R232fs and p.Y287* variants actually exhibited a distinct 296 binding pattern than the full-length p.G365R variant and wildtype RUNX1.

In summary, we comprehensively described *RUNX1* germline variants in childhood ALL. Using multiple functional assays, we identified highly deleterious germline variants in T-ALL and their biochemical and cellular effects. In addition, we characterized somatic genomic alterations associated with *RUNX1* germline variation in T-ALL, illustrating the interplay between acquired and inherited genetic variants in the context of leukemia pathogenesis.

303 Methods

304 **Patients**

305 A total of 6,190 ALL cases were included for RUNX1 targeted sequencing: 4,132 children with 306 newly diagnosed B-ALL enrolled on the Children's Oncology Group (COG) AALL0232 (n = 2,224), 307 P9904/5/6 (n = 1,634), and AALL0331 (n = 274) protocols; 704 children with newly diagnosed B-308 ALL enrolled on the St.Jude Total XIII and XV protocols: 1,231 children with newly diagnosed T-309 ALL enrolled on the COG AALL0434 protocols (1,231); and 123 children with newly diagnosed T-310 ALL enrolled on the St.Jude Total XIII and XV protocols (Figure 1A) (36-39). This study was 311 approved by institutional review boards at SJCRH and COG affiliated institutions and informed 312 consent was obtained from parents, guardians, or patients, and assent from patients, as 313 appropriate. Family histories were not available for patients on the COG studies, and thus ALL 314 cases were considered to be sporadic. Germline DNA was extracted from peripheral blood or 315 bone marrow from children with ALL during remission.

316 For targeted RUNX1 sequencing in the sporadic ALL cohort, Illumina dual-indexed libraries were 317 created from the germline DNA of 6,190 children with ALL, and pooled in sets of 96 before 318 hybridization with customized Roche NimbleGene SeqCap EZ probes (Roche, Roche NimbleGen, 319 Madison, WI, USA) to capture the RUNX1 genomic region. Quantitative PCR was used to define 320 the appropriate capture product titer necessary to efficiently populate an Illumina HiSeg 2000 321 flowcell for paired-end 2x100 bp sequencing. Coverage of at least 20-fold depth was achieved 322 across the targeted RUNX1 locus for 99.2% of samples. Sequence reads in FASTQ format were 323 mapped and aligned using the Burrows-Wheeler Aligner (BWA)(40, 41), and genetic variants 324 were called using the GATK pipeline (version 3.1)(41), as previously described, and annotated 325 using the ANNOVAR program(42) with the annotation databases including RefSeq(43), 326 Polyphen2(44, 45) and SIFT(46). Non-coding, and synonymous coding variants were excluded 327 from further consideration for this study.

328 Genomic Analysis of Patient Samples

- 329 Whole-genome sequencing and RNA sequencing were performed for T-ALL cases with germline
- 330 RUNX1 variants, whenever available samples were identified. Whole genome seq was done for
- 331 matched germline and leukemia samples, whereas RNA-seq was done only for leukemia samples.
- 332 Briefly, DNA was purified using the QIAamp DNA Blood Mini Kit (Qiagen, 51104), and RNA was
- 333 purified using the RiboPure RNA Purification Kit (Thermo Fisher Scientific, AM1928). DNA (250-
- 1000 ng) and RNA (500-1000 ng) was sent to St. Jude Hartwell center for sequencing.
- 335 Details for functional experiments, leukemia modeling in mouse, genomic analyses, and other
- 336 experiments can be found in supplemental file.
- 337 More detailed methods can be found in supplemental files.

339 References

- Churchman ML, Qian M, Te Kronnie G, Zhang R, Yang W, Zhang H, et al. Germline
 Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic
 Leukemia. *Cancer Cell.* 2018;33(5):937-48 e8.
- Trevino LR, Yang W, French D, Hunger SP, Carroll WL, Devidas M, et al. Germline
 genomic variants associated with childhood acute lymphoblastic leukemia. *Nat Genet*.
 2009;41(9):1001-5.
- 346 3. Xu H, Zhang H, Yang W, Yadav R, Morrison AC, Qian M, et al. Inherited coding
 347 variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia
 348 in children. *Nat Commun.* 2015;6:7553.
- Perez-Andreu V, Roberts KG, Harvey RC, Yang W, Cheng C, Pei D, et al. Inherited
 GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and
 risk of relapse. *Nat Genet*. 2013;45(12):1494-8.
- 352 5. Perez-Andreu V, Roberts KG, Xu H, Smith C, Zhang H, Yang W, et al. A genome-wide
 association study of susceptibility to acute lymphoblastic leukemia in adolescents and
 young adults. *Blood*. 2015;125(4):680-6.
- Bapaemmanuil E, Hosking FJ, Vijayakrishnan J, Price A, Olver B, Sheridan E, et al. Loci
 on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute
 lymphoblastic leukemia. *Nat Genet*. 2009;41(9):1006-10.
- Migliorini G, Fiege B, Hosking FJ, Ma Y, Kumar R, Sherborne AL, et al. Variation at
 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and
 phenotype. *Blood.* 2013;122(19):3298-307.
- Reine Variations
 Qian M, Cao X, Devidas M, Yang W, Cheng C, Dai Y, et al. TP53 Germline Variations
 Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in
 Children. J Clin Oncol. 2018;36(6):591-9.
- Moriyama T, Metzger ML, Wu G, Nishii R, Qian M, Devidas M, et al. Germline genetic
 variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic
 genetic study. *Lancet Oncol.* 2015;16(16):1659-66.
- Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, and Speck NA. Disruption of
 the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and
 blocks definitive hematopoiesis. *Proc Natl Acad Sci U S A*. 1996;93(8):3444-9.
- Huang G, Shigesada K, Ito K, Wee HJ, Yokomizo T, and Ito Y. Dimerization with
 PEBP2beta protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation.
 EMBO J. 2001;20(4):723-33.
- Kanno T, Kanno Y, Chen LF, Ogawa E, Kim WY, and Ito Y. Intrinsic transcriptional
 activation-inhibition domains of the polyomavirus enhancer binding protein 2/core
 binding factor alpha subunit revealed in the presence of the beta subunit. *Mol Cell Biol.*1998;18(5):2444-54.
- 377 13. Owen CJ, Toze CL, Koochin A, Forrest DL, Smith CA, Stevens JM, et al. Five new
 378 pedigrees with inherited RUNX1 mutations causing familial platelet disorder with
 379 propensity to myeloid malignancy. *Blood.* 2008;112(12):4639-45.
- 380 14. Preudhomme C, Renneville A, Bourdon V, Philippe N, Roche-Lestienne C, Boissel N, et
 381 al. High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to
 382 familial platelet disorder. *Blood.* 2009;113(22):5583-7.

383 15. Nishimoto N, Imai Y, Ueda K, Nakagawa M, Shinohara A, Ichikawa M, et al. T cell 384 acute lymphoblastic leukemia arising from familial platelet disorder. Int J Hematol. 385 2010;92(1):194-7. 386 16. Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, et al. 387 Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to 388 develop acute myelogenous leukaemia. Nat Genet. 1999;23(2):166-75. 389 17. Grossmann V, Kern W, Harbich S, Alpermann T, Jeromin S, Schnittger S, et al. 390 Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia. 391 Haematologica. 2011;96(12):1874-7. 392 18. Brown AL, Arts P, Carmichael CL, Babic M, Dobbins J, Chong CE, et al. RUNX1mutated families show phenotype heterogeneity and a somatic mutation profile unique to 393 394 germline predisposed AML. Blood Adv. 2020;4(6):1131-44. 395 19. Huang G, Zhang P, Hirai H, Elf S, Yan X, Chen Z, et al. PU.1 is a major downstream 396 target of AML1 (RUNX1) in adult mouse hematopoiesis. Nat Genet. 2008;40(1):51-60. 397 20. Matreyek KA, Stephany JJ, and Fowler DM. A platform for functional assessment of 398 large variant libraries in mammalian cells. Nucleic Acids Res. 2017;45(11):e102. 399 Sanda T, Lawton LN, Barrasa MI, Fan ZP, Kohlhammer H, Gutierrez A, et al. Core 21. 400 transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute 401 lymphoblastic leukemia. Cancer Cell. 2012;22(2):209-21. 402 22. Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR, et al. The genomic 403 landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat 404 Genet. 2017;49(8):1211-8. 405 23. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, et al. The genetic 406 basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 407 2012;481(7380):157-63. 408 24. Michaud J, Wu F, Osato M, Cottles GM, Yanagida M, Asou N, et al. In vitro analyses of 409 known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with 410 predisposition to acute myelogenous leukemia: implications for mechanisms of 411 pathogenesis. Blood. 2002;99(4):1364-72. 412 Antony-Debre I, Duployez N, Bucci M, Geffroy S, Micol JB, Renneville A, et al. 25. 413 Somatic mutations associated with leukemic progression of familial platelet disorder with 414 predisposition to acute myeloid leukemia. Leukemia. 2016;30(4):999-1002. 415 26. Yoshimi A, Toya T, Kawazu M, Ueno T, Tsukamoto A, Iizuka H, et al. Recurrent 416 CDC25C mutations drive malignant transformation in FPD/AML. Nat Commun. 417 2014;5:4770. 418 Degryse S, de Bock CE, Cox L, Demever S, Gielen O, Mentens N, et al. JAK3 mutants 27. 419 transform hematopoietic cells through JAK1 activation, causing T-cell acute 420 lymphoblastic leukemia in a mouse model. *Blood*. 2014;124(20):3092-100. 421 28. Cornejo MG, Kharas MG, Werneck MB, Le Bras S, Moore SA, Ball B, et al. Constitutive 422 JAK3 activation induces lymphoproliferative syndromes in murine bone marrow 423 transplantation models. *Blood*. 2009;113(12):2746-54. 424 Booth CAG, Barkas N, Neo WH, Boukarabila H, Soilleux EJ, Giotopoulos G, et al. Ezh2 29. 425 and Runx1 Mutations Collaborate to Initiate Lympho-Myeloid Leukemia in Early 426 Thymic Progenitors. Cancer Cell. 2018;33(2):274-91 e8.

- Wang C, Oshima M, Sato D, Matsui H, Kubota S, Aoyama K, et al. Ezh2 loss propagates
 hypermethylation at T cell differentiation-regulating genes to promote leukemic
 transformation. *J Clin Invest.* 2018;128(9):3872-86.
- 430 31. Connelly JP, Kwon EM, Gao Y, Trivedi NS, Elkahloun AG, Horwitz MS, et al. Targeted
 431 correction of RUNX1 mutation in FPD patient-specific induced pluripotent stem cells
 432 rescues megakaryopoietic defects. *Blood.* 2014;124(12):1926-30.
- 433 32. Giambra V, Jenkins CR, Wang H, Lam SH, Shevchuk OO, Nemirovsky O, et al.
- 434 NOTCH1 promotes T cell leukemia-initiating activity by RUNX-mediated regulation of
 435 PKC-theta and reactive oxygen species. *Nat Med.* 2012;18(11):1693-8.
- Wilkinson AC, Ballabio E, Geng H, North P, Tapia M, Kerry J, et al. RUNX1 is a key
 target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL
 complex interaction. *Cell Rep.* 2013;3(1):116-27.
- 439 34. Gerritsen M, Yi G, Tijchon E, Kuster J, Schuringa JJ, Martens JHA, et al. RUNX1
 440 mutations enhance self-renewal and block granulocytic differentiation in human in vitro
 441 models and primary AMLs. *Blood Adv.* 2019;3(3):320-32.
- 442 35. Hyle J, Zhang Y, Wright S, Xu B, Shao Y, Easton J, et al. Acute depletion of CTCF
 443 directly affects MYC regulation through loss of enhancer-promoter looping. *Nucleic*444 *Acids Res.* 2019;47(13):6699-713.
- 445 36. Larsen EC, Devidas M, Chen S, Salzer WL, Raetz EA, Loh ML, et al. Dexamethasone
 446 and High-Dose Methotrexate Improve Outcome for Children and Young Adults With
 447 High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology
 448 Group Study AALL0232. *J Clin Oncol.* 2016;34(20):2380-8.
- 449 37. Bowman WP, Larsen EL, Devidas M, Linda SB, Blach L, Carroll AJ, et al. Augmented
 450 therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of
 451 Children's Oncology Group trial P9906. *Pediatr Blood Cancer*. 2011;57(4):569-77.
- 452 38. Pui CH, Sandlund JT, Pei D, Campana D, Rivera GK, Ribeiro RC, et al. Improved
 453 outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study
 454 XIIIB at St Jude Children's Research Hospital. *Blood.* 2004;104(9):2690-6.
- 455 39. Pui CH, Relling MV, Sandlund JT, Downing JR, Campana D, and Evans WE. Rationale
 456 and design of Total Therapy Study XV for newly diagnosed childhood acute
 457 lymphoblastic leukemia. *Ann Hematol.* 2004;83 Suppl 1:S124-6.
- 458 40. Li H, and Durbin R. Fast and accurate short read alignment with Burrows-Wheeler 459 transform. *Bioinformatics*. 2009;25(14):1754-60.
- 460 41. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The
 461 Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA
 462 sequencing data. *Genome Res.* 2010;20(9):1297-303.
- 463
 42. Wang K, Li M, and Hakonarson H. ANNOVAR: functional annotation of genetic
 464 variants from high-throughput sequencing data. *Nucleic Acids Res.* 2010;38(16):e164.
- 465 43. Pruitt KD, Brown GR, Hiatt SM, Thibaud-Nissen F, Astashyn A, Ermolaeva O, et al.
 466 RefSeq: an update on mammalian reference sequences. *Nucleic Acids Res.*467 2014;42(Database issue):D756-63.
- 468 44. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A
 469 method and server for predicting damaging missense mutations. *Nat Methods*.
 470 2010;7(4):248-9.
- 471 45. Adzhubei I, Jordan DM, and Sunyaev SR. Predicting functional effect of human missense
 472 mutations using PolyPhen-2. *Curr Protoc Hum Genet*. 2013;Chapter 7:Unit7 20.

- 473 46. Kumar P, Henikoff S, and Ng PC. Predicting the effects of coding non-synonymous
- 474 variants on protein function using the SIFT algorithm. *Nat Protoc*. 2009;4(7):1073-81.
- 475

477 Figures and figure legends



478

479 Figure 1. Germline RUNX1 variants in childhood B- and T-ALL. (A) CONSORT diagram of 480 the Children's Oncology Group (COG) and St. Jude Children's Research Hospital (St. Jude) 481 patients included in this study. (B) Protein domain plot of RUNX1 and the amino acid 482 substitutions predicted to result from the germline RUNX1 variants identified in this study. The 483 upper panel showed germline RUNX1 variants in B-ALL cases, and the lower panel showed 484 those in T-ALL cases. (C) Protein domain plot of RUNX1 and the germline RUNX1 variants identified previously in familial platelet disorder with associated myeloid malignancy (FPDMM). 485 486 Data were retrieved from recently published paper (18).



Figure 2. Germline *RUNX1* variants influence transcription factor activity, subcellular
 localization, and CBFβ interaction. (A) Luciferase reporter gene assay (driven by the *PU.1* promoter in Hela cells) showed minimal effects on transcription factor activity by missense *RUNX1*

491 variants identified in B-ALL. (B) By contrast, 6 of 11 RUNX1 variants observed in T-ALL resulted in complete or partial loss of activity, as measured using luciferase reporter gene assay. (C) 492 493 Design of the Jurkat landing-pad system to measure RUNX1 variant activity in T-ALL. RUNX1 494 (either WT or variant) was inserted at the AAVS locus. EGFP coding sequence was knocked at 495 the 3'-end of GZMA, a RUNX1 target gene. RUNX1 transcription factor activity was determined 496 by flow cytometry of GFP signal which reflects RUNX1-driven GZMA transcription. (D) Flow 497 cytometry analysis of Jurkat cells expressing different RUNX1 variants. Cells harboring dominant 498 negative, loss of function, and WT like RUNX1 variants exhibited the lowest, moderate, and 499 highest GFP signals, respectively. (E) The GFP signal from Jurkat cells expressing each RUNX1 500 variant (relative to empty vector) is shown in bar graph, with error bars indicating 501 standard deviation of triplicates. (F) Immunofluorescence microscopy shows subcellular 502 localization of mCherry-tagged variant proteins and EGFP-tagged WT RUNX1. Variant and WT 503 RUNX1 were fused to mCherry and EGFP and expressed transiently in HEK293T cells, which 504 were then subjected to imaging analyses. (G) Co-immunoprecipitation assay was performed to 505 determine RUNX1-CBF^β interaction for each deleterious variant. Experiments were performed in 506 HEK293T cells. RUNX1 proteins were pulled down using anti-FLAG antibody and the presence 507 or absence of CBF β in the pellet was examined by immunoblotting.







518 containing 20% BIT9500, 10 ng/mL FLT-3 ligand, TPO, SCF, IL-3, and IL-6. The number of cells 519 was counted every week for 5 weeks. (D) Apoptosis of RUNX1-transduced CD34+ cells after 7 520 and 16 days of culture (same culture medium as C) was measured by flow cytometry using 521 Annexin-V and DAPI antibodies. (E-F) CD34+ cells ectopically expressing RUNX1 variants were 522 also subjected to in vitro differentiation assays for megakaryocyte or T cell lineages. Following 523 RUNX1 transduction, cells were cultured in the presence of SFEMII containing megakaryocyte 524 expansion supplement or T-Cell progenitor differentiation supplement for 2 weeks. 525 Megakaryocyte (E) was identified as CD41a+/CD42b+, and T cells (F) were defined as 526 CD5+/CD7+ by flow cytometry.



527

Figure 4. *RUNX1* variants have highly distinctive DNA binding patterns and associated with altered post-translational modifications. (A-B) Schematic representation of engineered Jurkat cell models for RUNX1 binding profiling studies. Variants (p.R232fs, p.Y287*, and p.G365R) were knocked in using CRISPR-cas9 editing at the endogenous locus in a heterozygous fashion. Meanwhile TY1 and HA epitopes were inserted to the coding sequence of WT and variant RUNX1, respectively. This design enables ChIP-seq of each protein simultaneously using two different antibodies. (C) ChIP-seq using HA antibody (recognizing RUNX1 variant) or TY1 antibody (for

wildtype RUNX1) showed that activation domain truncating variant RUNX1 (p.R232fs and p.Y287*) recognized largely identical genomic regions as missense variant p.G365R and wildtype RUNX1. Cells with homozygous WT genotype were used as control. (D) Pearson's correlation of WT and variant RUNX1 ChIP-seq signals (HA divided by TY1). (E) Predicted post translational modification of the p.G365R protein showed arginine methylation resulting from the single nucleotide variant. (F) Arginine mono-methylation was confirmed by immunoblotting using an anti-Mono-Methyl Arginine antibody.



Figure 5. Somatic JAK3 mutations co-occurs in T-ALL with germline RUNX1 variants and jointly drive ETP phenotype in mouse models. (A) Somatic JAK3 mutations were significantly enriched in T-ALL cases with germline RUNX1 variants. Whole genome seq of remission samples for 17 T-ALL cases, 6 and 11 with germline variants or somatic mutations in RUNX1, respectively.

547 (B) RNA-seq was analyzed for 267 T-ALL cases, including 252, 4, and 11 subjects with WT 548 RUNX1, carrying germline variants or somatic mutations in this gene. Unsupervised clustering 549 shows that RUNX1-variant cases, either germline or somatic, clustered tightly with T-ALL with 550 ETP and near-ETP immunophenotypes. (C) Upper panel: examples of blood smear of JAK3^M and JAK3^MRUNX1^M mice at the time of sacrifice, and control mice after 4 months of transplantation. 551 Lower panel: the percentage of mice developed leukemia in each group. JAK3^M: 100%, 5 out of 552 5; $JAK3^{M}RUNX1^{M}$: 66.7%, 4 out of 6. (D) Peripheral leukocyte count of $JAK3^{M}RUNX1^{M}$ (n = 4) 553 554 and $JAK3^{M}$ (n = 5) at the time of sacrifice, and control (n = 7) mice after 4 months of transplantation. (E) Spleen weight of $JAK3^{M}RUNX1^{M}$ (n = 4), and $JAK3^{M}$ (n = 5) mice at the time of sacrifice and 555 556 control mice (n = 4) after 4 months of transplantation. (F and G) Thymocyte immunophenotype of JAK3^M and JAK3^M RUNX1^M mice at the time of sacrifice. Co-expression of RUNX1^M and JAK3^M 557 558 resulted in a drastic increase in DN1 population compared with mice receiving LSK cells 559 expressing JAK3^M only. (H) In peripheral blood, bone marrow, and spleen, JAK3^MRUNX1^M mice 560 showed a significant increase in Mac1+ population and a reduction of the CD3+ population 561 compared to $JAK3^{M}$ mice.

562 **Table 1. Germline RUNX1 variants in pediatric ALL cases**

Protein (NM 001754)	CHROM	POS	REF	ALT	ExonicFunc.refGene	ALL Subtype (n = case number)	Allele frequence in gnomAD	Polyphen2 HDIV pred	SIFT pred
p.L472P	21	36164460	Α	G	missense	B-ALL (2)	1.99E-04	Probably damaging	Deleterious
p.L441R	21	36164553	Α	С	missense	B-ALL (1)	7.28E-06	Probably damaging	Deleterious
p.G438S	21	36164563	С	Т	missense	B-ALL (1)		Probably damaging	Tolerated
p.S410L	21	36164646	G	Α	missense	B-ALL (1)	1.56E-05	Probably damaging	Deleterious
p.S399I	21	36164679	С	Α	missense	B-ALL (1)	1.74E-05	Probably damaging	Deleterious
p.M368delinsIGM	21	36164771	С	CATGCCC	nonframeshift insertion	B-ALL (1)	7.34E-05		
p.M347I	21	36164834	С	т	missense	B-ALL (1)	8.79E-06	Benign	Deleterious
p.D344N	21	36164845	С	т	missense	B-ALL (1)	6.20E-05	Probably damaging	Tolerated
p.Q335H	21	36164870	С	A	missense	B-ALL (5) and T-ALL (1)	1.70E-04	Probably damaging	Deleterious
p.D332H	21	36164881	С	G	missense	B-ALL (1)	4.73E-06	Probably damaging	Deleterious
p.A329T	21	36164890	С	т	missense	B-ALL (1) and T-ALL (1)		Possibly damaging	Tolerated
p.T323A	21	36171598	Т	С	missense	B-ALL (1)	1.59E-05	Benian	
p.S319N	21	36171609	С	т	missense	B-ALL (1)		Possibly damaging	Tolerated
p.S318A	21	36171613	Α	С	missense	B-ALL (8) and T-ALL (2)	8.13E-04	Possibly damaging	Tolerated
p.A307∨	21	36171645	G	A	missense	B-ALL (1)		Possibly damaging	Tolerated
p.P278S	21	36171733	G	Α	missense	B-ALL (1)	1.19E-05	Possibly damaging	Tolerated
p.P275L	21	36171741	G	Α	missense	B-ALL (2) and T-ALL (1)	2.03E-04	Possibly damaging	Tolerated
p.M2671	21	36206711	С	Т	missense	B-ALL (1)	3.93E-05	Benian	Tolerated
p.R250H	21	36206763	С	Т	missense	B-ALL (2)	3.91E-05	Probably damaging	Tolerated
p.T246M	21	36206775	G	Α	missense	B-ALL (2) and T-ALL (2)	4.61E-05	Probably damaging	Tolerated
p.R233H	21	36206814	С	т	missense	B-ALL (1)	1.67E-04	Probably damaging	Tolerated
p.E223G	21	36206844	т	С	missense	B-ALL (2)	1.24E-04	Probably damaging	Deleterious
p.A187T	21	36231825	С	т	missense	B-ALL (1)	3.98E-06	Probably damaging	Deleterious
p.N159D	21	36252887	Т	С	missense	B-ALL (1)		Probably damaging	Deleterious
p.G87C	21	36259232	С	Α	missense	B-ALL (1)		Probably damaging	Deleterious
p.H85N	21	36259238	G	т	missense	B-ALL (1)	3.59E-05	Probably damaging	Deleterious
p.E80A	21	36259252	т	G	missense	B-ALL (1)	1.22E-05	Possibly damaging	Deleterious
p.A60V	21	36259312	G	Α	missense	B-ALL (1)	7.40E-05	Possibly damaging	Tolerated
p.M52K	21	36259336	Α	т	missense	B-ALL (12) and T-ALL (5)	2.46E-04	Probably damaging	Deleterious
p.122K	21	36265254	Α	т	missense	B-ALL (4) and T-ALL (1)	4.01E-06	Benian	Tolerated
p.S12L	21	36421162	G	A	missense	B-ALL (1)	3.98E-06	Benign	Tolerated
p.M418V	21	36164623	Т	С	missense	T-ALL (2)		Benign	Deleterious
p.G365R	21	36164782	С	G	missense	T-ALL (1)	9.73E-06	Probably damaging	Deleterious
p.P359R	21	36164799	G	С	missense	T-ALL (1)		Probably damaging	Deleterious
p.313 317del	21	36171614	ITCTGC/	A	nonframeshift deletion	T-ALL (2)	1.73E-04		
p.Y287X	21	36171704	G	С	stopgain	T-ALL (1)			Tolerated
p.R232fs	21	36206815	GC	G	frameshift deletion	T-ALL (1)			
p.Q213fs	21	36206874	TG	Т	frameshift deletion	T-ALL (1)			
p.N153Y	21	36252905	Т	Α	missense	T-ALL (1)		Probably damaging	Deleterious
p.S141fs	21	36252939	С	CGGTT	frameshift insertion	T-ALL (1)	2.39E-05		
p.K117X	21	36259142	т	Α	stopgain	T-ALL (1)			Tolerated
p.28 28del	21	36265234	TAGA	Т	nonframeshift deletion	T-ALL (1)	4.62E-05		

563

564 Polyphen2, Polymorphism Phenotyping v2; SIFT, Sorting Intolerant From Tolerant.